• 1448 引用
  • 18 h指数
20002019
Pureに変更を加えた場合、すぐここに表示されます。

Fingerprint Hiroyuki Yasudaが取り組む研究トピックをご確認ください。これらのトピックラベルは、この人物の研究に基づいています。これらを共に使用することで、固有の認識が可能になります。

  • 4 同様のプロファイル
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Mutation Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Lung Medicine & Life Sciences
Insertional Mutagenesis Medicine & Life Sciences

ネットワーク 最近の共同研究。丸をクリックして詳細を確認しましょう。

研究成果 2000 2019

  • 1448 引用
  • 18 h指数
  • 62 Article
1 引用 (Scopus)

A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients

Tani, T., Naoki, K., Yasuda, H., Arai, D., Ishioka, K., Ohgino, K., Yoda, S., Nakayama, S., Satomi, R., Terai, H., Ikemura, S., Sato, T. & Soejima, K., 2019 1 1, (Accepted/In press) : : Cancer Chemotherapy and Pharmacology.

研究成果: Article

Chemotherapy
Non-Small Cell Lung Carcinoma
Cells
Drug Therapy
Mutation
1 引用 (Scopus)

Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts

Hegab, A. E., Ozaki, M., Kameyama, N., Gao, J., Kagawa, S., Yasuda, H., Soejima, K., Yin, Y., Guzy, R. D., Nakamura, Y., Ornitz, D. M. & Betsuyaku, T., 2019 1 1, : : Journal of Pathology.

研究成果: Article

Fibroblast Growth Factor Receptors
Fibroblast Growth Factors
Neoplasms
Lung
Cancer-Associated Fibroblasts
6 引用 (Scopus)

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

Hasegawa, H., Yasuda, H., Hamamoto, J., Masuzawa, K., Tani, T., Nukaga, S., Hirano, T., Kobayashi, K., Manabe, T., Terai, H., Ikemura, S., Kawada, I., Naoki, K. & Soejima, K., 2019 1 1, : : Lung Cancer. 127, p. 146-152 7 p.

研究成果: Article

Insertional Mutagenesis
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Exons
Therapeutics

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations

Ikemura, S., Yasuda, H., Matsumoto, S., Kamada, M., Hamamoto, J., Masuzawa, K., Kobayashi, K., Manabe, T., Arai, D., Nakachi, I., Kawada, I., Ishioka, K., Nakamura, M., Namkoong, H., Naoki, K., Ono, F., Araki, M., Kanada, R., Ma, B., Hayashi, Y. および8人, Mimaki, S., Yoh, K., Kobayashi, S. S., Kohno, T., Okuno, Y., Goto, K., Tsuchihara, K. & Soejima, K., 2019 5 14, : : Proceedings of the National Academy of Sciences of the United States of America. 116, 20, p. 10025-10030 6 p.

研究成果: Article

公開
Molecular Dynamics Simulation
Lung Neoplasms
Mutation
Pharmaceutical Preparations
Protein-Tyrosine Kinases

Monomer preference of EGFR tyrosine kinase inhibitors influences the synergistic efficacy of combination therapy with cetuximab

Oashi, A., Yasuda, H., Kobayashi, K., Tani, T., Hamamoto, J., Masuzawa, K., Manabe, T., Terai, H., Ikemura, S., Kawada, I., Naoki, K. & Soejima, K., 2019 1 1, : : Molecular cancer therapeutics. 18, 9, p. 1593-1601 9 p.

研究成果: Article

Dimerization
Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Therapeutics